.jpg)
Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges
A concise report featuring insights from the prominent thought leaders of Biologics 2024
Top R&D Stories of 2023
Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Antibody & Protein Engineering
Recommended Approval for AbbVie’s Rinvoq Treatment
AbbVie announces official recommended approval of it Rinvoq treatment for adults with active non-radiographic axial spondyloarthritis.
Bioanalysis
The Countdown Begins: How ADCs will Become the Next Generation of Biologics Therapeutics
Key opinion leaders from AbbVie, Ambrx Inc, and Antikor Biopharma talk about the cutting-edge technology’s promise for better therapeutic index.
NextGen Therapeutics
Why Drug Delivery is Key to New Drug Discovery
Method of delivery is just as important as discovering new medicines.
Q & A with Derek O'Hagan
We interview Derek O'Hagan, Senior Advisor at GlaxoSmithKline Vaccines to learn more about the future of the vaccine.
Most Anticipated Presentations: Vaccines Europe
Discover key event highlights from Oxford Global's upcoming Vaccines Congress 2022.
Peptide Chemistry
Oral Delivery of Peptides
Nazneen Dewji, President and CEO of Cenna Biosciences leads a discussion on the strategies to overcome the challenges ‘Oral Delivery of Peptides’.
Antibody & Protein Engineering
Top 3 Biologics News Headlines
Hot off the press, we look at this week’s breaking news stories from the Biologics industry.
Antibody & Protein Engineering
Delays for New COVID Drugs
Clinical studies testing treatments for severe COVID-19 face major delays due to eligibility issues.
Antibody & Protein Engineering
Bispecific CAR-T Cell Therapies: Successful Applications in Mouse Tumour Models
Two roadblocks to the successful application of treatments for tumourous tissues are heterogenous antigen expression and antigen loss. Bispecific CAR-T cells, capable of simultaneously binding to two different antigens via heavy chain-only domains, may present a solution.
FDA Approves GSK’s MMR Vaccine
The FDA gives the green light to GSK’s measles, mumps, and rubella vaccine, providing US clinicians with a new treatment option for childhood inoculation for first time in more than 50 years.
NextGen Therapeutics
Broadening Horizons for Bispecific Effector Cell Redirection
Key opinion leaders share their thoughts on the prospect of effector cell redirection and cell engagers at Biologics UK: In-Person 2022.